

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 2 DECEMBER 2025 AND ELECTION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) is pleased to announce the poll results of the 2025 second extraordinary general meeting (the “**EGM**”) held at 1:30 p.m. on Tuesday, 2 December 2025 at Sky Fortune Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC.

References are made to the circular of the Company (the “**Circular**”) and the notice of the EGM, both dated 7 November 2025. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record date of the EGM, (i) the total number of issued shares of the Company (“**Shares**”) was 2,670,429,325 Shares, comprising 2,118,488,825 A Shares and 551,940,500 H Shares; and (ii) the holders of 2,639,554,073 Shares (comprising 2,098,582,573 A Shares and 540,971,500 H Shares) (or by authorised proxies) were entitled to attend and vote on the resolution proposed at the EGM. There were no Shares entitling the Shareholders to attend and vote only against the resolution at the EGM.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, as at the record date for the EGM, no Shareholder had any material interest in the resolution proposed at the EGM and was required to abstain from voting at the EGM. No Shareholder has stated in the circular his/her/its intention to vote against any resolution or abstain from voting at the EGM.

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorised proxies present at the EGM:

Number of Shareholders and authorised proxies	1,726
<i>Including:</i> Number of A Shareholders	1,725
Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)	1,081,006,672
<i>Including:</i> Total number of Shares carrying voting rights held by A Shareholders (shares)	952,051,193
Total number of Shares carrying voting rights held by H Shareholders (shares)	128,955,479
Percentage of the total number of Shares carrying voting rights (%)	40.9541
<i>Including:</i> Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	36.0686
Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	4.8855

The EGM was convened in compliance with the requirements of the Company Law and the Articles of Association, and was chaired by Mr. Chen Yuqing, the chairman of the Company. The Company has eleven (11) directors in office (excluding Mr. Liu Yi, who was formally elected as an executive Director of the tenth session of the Board at the EGM), eight (8) Directors of the Company, including three (3) executive Directors, namely Mr. Chen Yuqing, Ms. Guan Xiaohui and Mr. Wen Deyong; four (4) independent non-executive Directors, namely Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and one (1) employee Director, namely Ms. Yan Jia, attended the EGM.

In compliance with the requirements of the Hong Kong Listing Rules and Article 108 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers and the Shareholder's representatives acted as the scrutineers for the vote-counting at the EGM.

Note regarding the scope of work of BDO Limited: The poll results were subject to scrutiny by BDO Limited, Certified Public Accountants (Practising), whose work was limited to certain procedures requested by the Company to agree the poll results summary prepared by the Company to poll forms collected and provided by the Company to BDO Limited. The work performed by BDO Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants nor did it include provision of any assurance or advice on matters of legal interpretation or entitlement to vote.

POLL RESULTS OF THE EGM

The resolution at the EGM was voted on by poll. The poll results in respect of the resolution proposed at the EGM were as follows:

ORDINARY RESOLUTION		Number of valid votes		
		For	Against	Abstain
1.	To elect Mr. Liu Yi as an executive Director.	1,075,374,973 (99.4790%)	5,300,197 (0.4903%)	331,502 (0.0307%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the convening and holding of the EGM are in compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

ELECTION OF EXECUTIVE DIRECTOR

At the EGM, Mr. Liu Yi (“**Mr. Liu**”) was duly elected by the Shareholders as an executive Director of the tenth session of the Board, and the appointment is effective from 2 December 2025 until the term of the current session of the Board expires.

The biographical details of Mr. Liu as at the date of this announcement are listed as follows:

Mr. Liu, aged 50, is currently an executive Director, chief executive officer and president of the Company, chairman and chief executive officer of the MedTech division* (診療科技事業部), co-chairman of the Innovative Medicine division, and holds directorships and management positions in certain subsidiaries of the Company, including serving as an executive director and the chairman of the board of directors of Sisram Medical Ltd (stock code: 01696), a company listed on the Hong Kong Stock Exchange, and a non-executive director of Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司) (stock code: 02696), a company listed on the Hong Kong Stock Exchange.

Mr. Liu joined the Group in November 2015 and served as the chief technology officer of the medical devices division and in other positions of the Company. He was a vice president of the Company from January 2017 to January 2022, a senior vice president of the Company from January 2022 to June 2025, and has been the chief executive officer and president of the Company since June 2025 and an executive Director of the Company since December 2025. Prior to joining the Group, Mr. Liu was

mainly engaged in the field of medical devices and medical diagnostics. Mr. Liu obtained a bachelor's degree in engineering from Beijing Institute of Technology, a master's degree in management from Peking University and a doctorate degree in biomedical engineering from Beihang University.

Mr. Liu has confirmed that, save as disclosed above, as at the date of this announcement, he does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not hold any other positions in the Company or any of its subsidiaries nor any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

The Company will enter into a relevant executive Director's service contract with Mr. Liu commencing from the date of the Shareholders' approval for Mr. Liu's appointment at the EGM up to the expiration of the term of the tenth session of the Board. Mr. Liu will not receive any remuneration from the Company for his appointment as an executive Director, and the relevant director's service contract will not provide for a specific remuneration amount.

Mr. Liu has confirmed that, as at the date of this announcement, Mr. Liu is interested in an aggregate of 35,444 Shares (including 15,444 A Shares and 20,000 H Shares), 326,900 A share options and 762,800 H shares restricted share units of the Company. Save as disclosed above, Mr. Liu does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules, nor any other matters relating to the appointment of Mr. Liu as an executive Director that need to be brought to the attention of the Shareholders.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
2 December 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* For identification purposes only